ABPRO Holdings Inc

ABP

5.620USD

+0.005+0.09%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

ABPRO Holdings Inc's Score

Industry at a Glance

Industry Ranking

130 / 407

Overall Ranking

258 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

2.000

Target Price

+954.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ABPRO Holdings Inc Highlights

StrengthsRisks

Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Growing

The company is in a growing phase, with the latest annual income totaling USD 183.00K.

Fairly Valued

The company’s latest PE is -6.73, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 59.45K shares, decreasing 49.36% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 10.67K shares of this stock.

The company's current financial score is 6.32, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.32

Change

0



Financials

3.39

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.16

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.55

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 8.14, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.73, which is -100.00% below the recent high of 0.00 and -1125.01% above the recent low of -82.48.

Score

Industry at a Glance

Previous score

8.14

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 130/407

No Data

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for ABPRO Holdings Inc is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.94, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 8.01 and the support level at 1.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.96

Change

-0.02

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-07

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Abpro Bio International Inc

16.51M

--

Chan (Ian)

9.25M

--

Atlantic Coastal Acquisition Management II LLC

3.48M

--

The Vanguard Group, Inc.

Star Investors

80.56K

--

Cantor Fitzgerald, L.P

600.00K

--

Suk (Jin Wook)

212.16K

-70.21%

Geode Capital Management, L.L.C.

196.49K

+127.59%

Jane Street Capital, L.L.C.

93.93K

--

Polar Asset Management Partners Inc.

87.50K

-80.45%

AQR Capital Management, LLC

87.50K

--



1

2



The company’s current risk assessment score is 1.46, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

ABPRO Holdings Inc

ABP

6.24 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment